காந்த அதிர்வு இமேஜிங் படிப்பு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Clene Nanomedicine to Present Updated Interim Data from Phase 2 Multiple Sclerosis Programs at .
Clene Inc.February 19, 2021 GMT
SALT LAKE CITY, Feb. 19, 2021 (GLOBE NEWSWIRE) Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company, today announced that it will present updated interim data from its REPAIR-MS study and updated blinded interim data from its VISIONARY-MS study in poster presentations at the Americas Committee for Treatment and Research in Multiple Sclerosis’ ACTRIMS Forum 2021 (“ACTRIMS”) taking place virtually from February 25-27, 2021. ....

Salt Lake City , United States , Andrew Mielach , Robert Glanzman , Bruce Mackle , Lifesci Advisors , Research In Multiple Sclerosi , Americas Committee For Treatment , Clene Nanomedicine Inc , Exchange Commission , Lifesci Communications , Clene Inc , University Of Texas Southwestern Medical Center , Clene Nanomedicine , Americas Committee , Multiple Sclerosi , Patients Treated , Interim Results , Magnetic Resonance Imaging Study , Chief Medical Officer , Catalytic Gold Nanocrystals , Chronic Optic Neuropathy , Multiple Sclerosis Functional Composite , Texas Southwestern Medical Center , North East , Private Securities Litigation Reform Act ,